A closer look at “Roche's Divarasib Shows Impressive Lung Cancer Results at ESMO 2024”, exactly as the source publishes it. Roche's investigational KRAS inhibitor divarasib delivered one of the standout data sets at this year's European Society for Medical Oncology (ESMO) congress, marking a significant advance in the treatment of KRAS-mutant non-small cell lung cancer. The study results, presented at the global oncology The study results, presented at the global oncology meeting, highlight the drug's potential to become a best-in-class therapy in a space that has challenged researchers for decades.
Divarasib targets the KRAS G12C mutation, a common driver in lung adenocarcinoma, and its clinical performance suggests robust efficacy and a manageable safety profile. This development matters because KRAS was long considered undruggable, and only a handful of inhibitors have reached the market. Roche's entry could intensify competition and expand options for patients who often develop resistance to existing therapies. The full version stays on the original page, which this listing opens directly.